Imatinib mesylate (Gleevec) induced remission in Philadelphia chromosome-negative BCR-ABL negative atypical chronic myelogenous leukemia (CML).

被引：0
|
作者：
Seftel, MD
Horsman, DE
Berry, B
Parslow, M
Pewarchuk, WJ
Nantel, SH
机构：
[1] Vancouver Gen Hosp, Leukemia BMT Program British Columbia, Vancouver, BC, Canada
[2] British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada
[3] Capital Hlth Reg, Dept Pathol, Victoria, BC, Canada
[4] Cowichan Community Canc Ctr, Cowichan, BC, Canada
[5] Univ British Columbia, Dept Med, Vancouver, BC V5Z 1M9, Canada
来源：
BLOOD | 2002年 / 100卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4856
引用
收藏
页码：326B / 327B
页数：2
相关论文
共 50 条
  • [1] Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate
    Mats Hardling
    Yuan Wei
    Lars Palmqvist
    Birgitta Swolin
    Dick Stockelberg
    Bengt Gustavsson
    Kerstin Ekeland-Sjöberg
    Hans Wadenvik
    Anne Ricksten
    Medical Oncology, 2004, 21 : 349 - 358
  • [2] Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate
    Hardling, M
    Wei, Y
    Palmqvist, L
    Swolin, B
    Stockelberg, D
    Gustavsson, B
    Ekeland-Sjöberg, K
    Wadenvik, H
    Ricksten, A
    MEDICAL ONCOLOGY, 2004, 21 (04) : 349 - 358
  • [3] A novel BCR-ABL, fusion gene (e6a2) in a patient with Philadelphia chromosome-negative chronic myelogenous leukemia
    Hochhaus, A
    Reiter, A
    Skladny, H
    Melo, JV
    Sick, C
    Berger, U
    Guo, JQ
    Arlinghaus, RB
    Hehlmann, R
    Goldman, JM
    Cross, NCP
    BLOOD, 1996, 88 (06) : 2236 - 2240
  • [4] Characteristics and outcome of patients with Philadelphia chromosome negative, bcr/abl negative chronic myelogenous leukemia
    Onida, F
    Ball, G
    Kantarjian, HM
    Smith, TL
    Glassman, A
    Albitar, M
    Scappini, B
    Rios, MB
    Keating, MJ
    Beran, M
    CANCER, 2002, 95 (08) : 1673 - 1684
  • [5] PHILADELPHIA CHROMOSOME-NEGATIVE CHRONIC MYELOGENOUS LEUKEMIA AND CHRONIC MYELOMONOCYTIC LEUKEMIA
    KANTARJIAN, HM
    KURZROCK, R
    TALPAZ, M
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 1990, 4 (02) : 389 - 404
  • [6] Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia
    Donato, NJ
    Wu, JY
    Stapley, J
    Lin, H
    Arlinghaus, R
    Aggarwal, B
    Shishodin, S
    Albitar, M
    Hayes, K
    Kantarjian, H
    Talpaz, M
    CANCER RESEARCH, 2004, 64 (02) : 672 - 677
  • [7] Management of imatinib mesylate-resistances induced by BCR-ABL mutations in chronic myelogenous leukemia
    Nicolini, Franck-Emmanuel
    Ducastelle, Sophie
    Corm, Selim
    HEMATOLOGIE, 2007, 13 (06): : 457 - 464
  • [8] Analysis of Philadelphia chromosome-negative BCR-ABL-positive chronic myelogenous leukemia by hypermetaphase fluorescence in situ hybridization
    Seong, D
    Kantarjian, HM
    Albitar, M
    Arlinghaus, R
    Xu, J
    Talpaz, M
    Rios, MB
    Guo, JQ
    O'Brien, S
    Siciliano, M
    ANNALS OF ONCOLOGY, 1999, 10 (08) : 955 - 959
  • [9] PHILADELPHIA CHROMOSOME-NEGATIVE CHRONIC MYELOGENOUS LEUKEMIA - A MORPHOLOGICAL REASSESSMENT
    PUGH, WC
    PEARSON, M
    VARDIMAN, JW
    ROWLEY, JD
    BRITISH JOURNAL OF HAEMATOLOGY, 1985, 60 (03) : 457 - 467
  • [10] ATYPICAL BCR-ABL TRANSCRIPTS IN 2 PATIENTS WITH PHILADELPHIA-CHROMOSOME NEGATIVE CHRONIC MYELOID-LEUKEMIA
    HOCHHAUS, A
    REITER, A
    SKLADNY, H
    ZENHAUSERN, R
    HEHLMANN, R
    GOLDMAN, JM
    CROSS, NCP
    EXPERIMENTAL HEMATOLOGY, 1995, 23 (08) : 932 - 932
12345